Stock listing
LS Exchange:A3C31Y GENinCode PLC Aktie
German listing (LS Exchange) of GENinCode PLC · home listing LSE:GENI
Follow GENinCode PLC into a list and get an email when it puts out news.
Home listing price · LSE:GENI
0.55p GBX (pence) -0.05 (-8.3%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, LSE:GENI
- Day range
- 0.50p – 0.60p GBX (pence)Nov 20, 2026
- Volume
- 2.20M sharesNov 20, 2026
- Market cap
- £4.14M GBPAt the close on Nov 20, 2026 · price × 753.0M shares outstanding
- 52-week range
- 0.50p – 4.90p GBX (pence)Lowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- £21,018 GBPMedian day 1.36M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| LSE:GENI · Home | 0.55p GBX (pence) | -0.05 (-8.3%) | 2,203,305 | 0.60p | 0.60p | 0.50p | 0.60p | Close on Nov 20, 2026 |
| Frankfurt:9PL | €0.0030 EUR | -0.0020 (-40.0%) | — | — | €0.0060 | — | €0.0050 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · LSE:GENI · GBX (pence), adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| 0.55p | -0.05 | -8.3% | 0.60p | 0.60p | 0.50p | 2,203,305 | |
| 0.60p | 0.00 | 0.0% | 0.60p | 0.60p | 0.55p | 55,528 | |
| 0.60p | 0.00 | 0.0% | 0.577p | 0.65p | 0.55p | 81,684 | |
| 0.60p | 0.00 | 0.0% | 0.65p | 0.65p | 0.56p | 136,022 | |
| 0.60p | +0.02 | +3.4% | 0.55p | 0.65p | 0.55p | 1,680,337 | |
| 0.58p | -0.02 | -3.3% | 0.65p | 0.65p | 0.55p | 142,203 | |
| 0.60p | 0.00 | 0.0% | 0.65p | 0.65p | 0.56p | 368,649 | |
| 0.60p | 0.00 | 0.0% | 0.63p | 0.65p | 0.55p | 30,706 | |
| 0.60p | 0.00 | 0.0% | 0.583p | 0.65p | 0.56p | 2,060,524 | |
| 0.60p | +0.02 | +3.4% | 0.598p | 0.60p | 0.55p | 5,455,341 | |
| 0.58p | +0.03 | +5.5% | 0.58p | 0.619p | 0.50p | 5,033,418 | |
| 0.55p | -0.10 | -15.4% | 0.607p | 0.70p | 0.518p | 7,991,461 | |
| 0.65p | 0.00 | 0.0% | 0.65p | 0.70p | 0.60p | 2,320,003 | |
| 0.65p | -0.01 | -1.5% | 0.70p | 0.70p | 0.60p | 296,697 | |
| 0.66p | 0.00 | 0.0% | 0.65p | 0.70p | 0.621p | 821,230 | |
| 0.66p | -0.04 | -5.7% | 0.65p | 0.67p | 0.62p | 1,402,098 | |
| 0.70p | 0.00 | 0.0% | 0.652p | 0.75p | 0.652p | 311,276 | |
| 0.70p | -0.025 | -3.4% | 0.80p | 0.80p | 0.65p | 5,985,976 | |
| 0.725p | 0.00 | 0.0% | 0.745p | 0.80p | 0.65p | 1,297,669 | |
| 0.725p | +0.10 | +16.0% | 0.60p | 0.85p | 0.60p | 7,904,894 | |
| 0.625p | -0.025 | -3.8% | 0.65p | 0.65p | 0.60p | 564,504 | |
| 0.65p | -0.025 | -3.7% | 0.675p | 0.70p | 0.612p | 4,233,805 | |
| 0.675p | +0.075 | +12.5% | 0.60p | 0.70p | 0.575p | 3,865,641 | |
| 0.60p | -0.025 | -4.0% | 0.625p | 0.65p | 0.561p | 1,374,835 | |
| 0.625p | 0.00 | 0.0% | 0.625p | 0.636p | 0.625p | 79,436 | |
| 0.625p | 0.00 | 0.0% | 0.625p | 0.65p | 0.60p | 109,277 | |
| 0.625p | 0.00 | 0.0% | 0.625p | 0.637p | 0.601p | 529,109 | |
| 0.625p | 0.00 | 0.0% | 0.625p | 0.65p | 0.601p | 220,851 | |
| 0.625p | 0.00 | 0.0% | 0.625p | 0.65p | 0.60p | 1,007,932 | |
| 0.625p | 0.00 | 0.0% | 0.625p | 0.65p | 0.60p | 277,433 | |
| 0.625p | 0.00 | 0.0% | 0.625p | 0.65p | 0.588p | 360,021 | |
| 0.625p | -0.05 | -7.4% | 0.675p | 0.70p | 0.605p | 2,336,078 | |
| 0.675p | -0.025 | -3.6% | 0.70p | 0.72p | 0.65p | 2,764,493 | |
| 0.70p | 0.00 | 0.0% | 0.70p | 0.75p | 0.65p | 311,245 | |
| 0.70p | 0.00 | 0.0% | 0.70p | 0.75p | 0.65p | 966,851 | |
| 0.70p | 0.00 | 0.0% | 0.70p | 0.75p | 0.65p | 2,249,511 | |
| 0.70p | 0.00 | 0.0% | 0.70p | 0.75p | 0.65p | 1,356,034 | |
| 0.70p | -0.175 | -20.0% | 0.80p | 0.80p | 0.636p | 22,954,144 | |
| 0.875p | 0.00 | 0.0% | 0.875p | 0.899p | 0.854p | 94,424 | |
| 0.875p | 0.00 | 0.0% | 0.875p | 0.90p | 0.854p | 718,082 | |
| 0.875p | 0.00 | 0.0% | 0.875p | 0.90p | 0.85p | 1,801,413 | |
| 0.875p | 0.00 | 0.0% | 0.875p | 0.90p | 0.85p | 1,359,025 | |
| 0.875p | 0.00 | 0.0% | 0.875p | 0.90p | 0.854p | 99,515 | |
| 0.875p | -0.025 | -2.8% | 0.90p | 0.92p | 0.85p | 2,012,713 | |
| 0.90p | +0.05 | +5.9% | 0.85p | 0.95p | 0.80p | 5,287,333 | |
| 0.85p | +0.025 | +3.0% | 0.825p | 0.85p | 0.80p | 1,012,902 | |
| 0.825p | -0.025 | -2.9% | 0.85p | 0.85p | 0.80p | 999,259 | |
| 0.85p | 0.00 | 0.0% | 0.85p | 0.90p | 0.80p | 3,569,064 | |
| 0.85p | 0.00 | 0.0% | 0.85p | 0.90p | 0.80p | 4,093,902 | |
| 0.85p | -0.10 | -10.5% | 0.95p | 0.97p | 0.813p | 5,699,294 | |
| 0.95p | 0.00 | 0.0% | 0.95p | 1.00p | 0.90p | 2,733,624 | |
| 0.95p | 0.00 | 0.0% | 0.95p | 1.00p | 0.90p | 4,532,754 | |
| 0.95p | 0.00 | 0.0% | 0.95p | 1.00p | 0.90p | 391,667 | |
| 0.95p | -0.075 | -7.3% | 1.025p | 1.10p | 0.90p | 2,894,231 | |
| 1.025p | +0.075 | +7.9% | 0.95p | 1.10p | 0.90p | 3,273,306 | |
| 0.95p | -0.025 | -2.6% | 0.975p | 1.00p | 0.90p | 943,134 | |
| 0.975p | -0.025 | -2.5% | 1.00p | 1.05p | 0.95p | 583,564 | |
| 1.00p | -0.05 | -4.8% | 1.05p | 1.10p | 0.95p | 3,756,693 | |
| 1.05p | +0.10 | +10.5% | 1.025p | 1.25p | 0.95p | 21,428,256 | |
| 0.95p | +0.075 | +8.6% | 0.875p | 0.98p | 0.825p | 5,708,782 | |
| 0.875p | -0.025 | -2.8% | 0.875p | 0.899p | 0.852p | 329,414 | |
| 0.90p | +0.025 | +2.9% | 0.875p | 0.90p | 0.85p | 3,578,240 | |
| 0.875p | 0.00 | 0.0% | 0.875p | 0.90p | 0.85p | 1,150,041 | |
| 0.875p | 0.00 | 0.0% | 0.875p | 0.90p | 0.856p | 2,102,440 | |
| 0.875p | -0.025 | -2.8% | 0.891p | 0.891p | 0.85p | 987,749 |
- Ticker
- LS Exchange:A3C31Y
- Asset type
- Stock
- Sector
- Health care
- Industry
- Diagnostics & research services
- Exchange
- LS Exchange
- Currency
- EUR
What changed lately
Latest news release · Nov 6, 2026
Holding(s) in Company
Latest earnings call · Jun 10, 2026
GENinCode (LSE:GENI) — Full year results briefing
Replay and transcript
Latest news
Holding(s) in Company
Nov 6, 2026
Closed 0.60p (+3.4%) on Nov 6, 2026
Half-year Financial Report
Sep 29, 2026
Closed 0.70p (-20.0%) on Sep 29, 2026
CARDIO inCode-Score milestone clinical results
Aug 28, 2026
Closed 1.05p (+10.5%) on Aug 28, 2026
Result of GM, Director Shareholdings and TVR
Feb 9, 2026
Closed 1.15p (0.0%) on Feb 9, 2026
Additional Subscription
Feb 6, 2026
Closed 1.15p (0.0%) on Feb 6, 2026
Result of Retail Offer
Jan 26, 2026
Closed 1.05p (-4.5%) on Jan 26, 2026
Result of Placing and Subscription
Jan 22, 2026
Closed 1.15p (-37.8%) on Jan 22, 2026
Retail Offer
Jan 21, 2026
Closed 1.15p (-37.8%) on Jan 22, 2026
Placing and Subscription
Jan 21, 2026
Closed 1.15p (-37.8%) on Jan 22, 2026
Collaboration with Sohin Genetics
Dec 17, 2025
Closed 2.80p (-1.8%) on Dec 17, 2025
GENinCode PLC on 6ix
- Sector
- Health care
- Industry
- Diagnostics & research services
- News releases
- 14 in the last 12 months · 68 in all · newest Nov 6, 2026 · oldest 2021
- Calls
- 10 calls with a replay · 10 with a transcript · latest Jun 10, 2026
Where GENinCode PLC is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| LSE:GENI · Home listing | LSE | United Kingdom | GBX |
| LS Exchange:A3C31Y · This page | LS Exchange | Germany | EUR |
| Lang & Schwarz:A3C31Y | Lang & Schwarz | Germany | EUR |
| Frankfurt:9PL | Frankfurt | Germany | EUR |
| Stuttgart:9PL | Stuttgart | Germany | EUR |
Valuation
EV/sales 0.7× against a median of 1.6×: 5th lowest of 10 Diagnostics & research services companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- £2.19M GBP
- P/E
- Loss
- EV/sales
- 0.7×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 2.0×
- Gross margin
- 50.0%
- Operating margin
- −191.6%
- Net margin
- −185.5%
- Debt to equity
- 0.1×
- Beta
- No index for this market yet
Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| GENinCode PLC · LSE:GENI | US$5.42M | US$2.86M | n/a | 0.7× | n/a | 2.0× | −185.5% | 0.1× | n/a |
| Milton Essex S.A. · NEWCONNECT:MTN | US$6.07M | US$6.06M | n/a | 17,573× | n/a | 0.5× | n/a | 0.0× | n/a |
| iXensor Co., Ltd. · TPEX:6734 | US$6.01M | US$5.63M | n/a | 6.9× | n/a | 23.1× | −174.7% | 0.9× | n/a |
| Cizzle Biotechnology Holdings PLC · LSE:CIZ | US$5.70M | US$5.59M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| AcouSort AB · OMXSTO:ACOU | US$5.69M | US$4.76M | n/a | 6.1× | n/a | 5.9× | −140.8% | 0.0× | n/a |
| Nanologica AB · OMXSTO:NICA | US$5.29M | US$8.67M | 2.9× | 1.6× | n/a | 0.3× | 34.9% | 0.3× | n/a |
| VivoSim Labs, Inc. · NASDAQ:VIVS | US$5.29M | −US$2.76M | n/a | −20.5× | n/a | 0.7× | n/a | 0.1× | 1.91 |
| Biomerica, Inc. · NASDAQ:BMRA | US$4.97M | US$2.23M | n/a | 0.5× | n/a | 1.4× | −115.5% | 0.0× | 0.71 |
| VolitionRx Limited · AMEX:VNRX | US$4.87M | US$9.19M | n/a | 2.7× | n/a | n/a | −698.5% | n/a | 1.52 |
| Boule Diagnostics AB · OMXSTO:BOUL | US$4.84M | US$24.70M | n/a | 0.6× | n/a | 0.3× | −4.0% | 1.3× | n/a |
| BioInfra Co.,Ltd. · KRX:199730 | US$4.75M | −US$509,202 | n/a | −0.0× | n/a | 0.5× | −32.3% | 0.0× | n/a |
| Median of the others | US$5.29M | US$5.61M | 2.9× | 1.6× | 0.6× | −115.5% | 0.0× | 1.52 |
Forecasts
Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.
- Price target
- 7.50 GBX · Analysts' mean
- EPS, year to Dec 2026
- -0.007 · 1 analyst
- Revenue, year to Dec 2026
- 3.2M · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Matthew Walls | Chief Executive Officer |
| Paul Foulger | Chief Financial Officer |
| Jordi Puig | Chief Operations Officer |
Board
| Director | Role |
|---|---|
| Bill Rhodes | Independent Non-Executive Chairman |
| Felix Frueh | Non-Executive Director |
| Huon Gray | Independent Non-Executive Director |
| Jordi Puig | Chief Operations Officer |
| Matthew Walls | Chief Executive Officer |
| Paul Foulger | Chief Financial Officer |
| Sergio Olivero | Independent Non-Executive Director |
Events
| Call | When | Status |
|---|---|---|
| GENinCode (LSE:GENI) — Full year results briefing | Wed, Jun 10, 2026 · 6:00 AM ET | Replay |
| GENinCode (LSE:GENI) — Interim results presentation | Thu, Oct 02, 2025 · 6:00 AM ET | Replay |
| GENinCode (LSE:GENI) — Full year results briefing | Thu, Jun 05, 2025 · 9:00 AM ET | Replay |
| GENinCode (LSE:GENI) — Interim results presentation | Wed, Sep 25, 2024 · 11:00 AM ET | Replay |
| GENinCode (LSE:GENI) — Full year results briefing | Tue, Jun 04, 2024 · 9:00 AM ET | Replay |
| GENinCode (LSE:GENI) — Interim results presentation | Wed, Sep 20, 2023 · 11:30 AM ET | Replay |
| GENinCode (LSE:GENI) — Final results presentation | Thu, Jun 08, 2023 · 9:00 AM ET | Replay |
| GENinCode (LSE:GENI) — Interim results - Investor presentation | Tue, Sep 27, 2022 · 11:30 AM ET | Replay |
| GENinCode (LSE:GENI) — Final results presentation | Tue, May 17, 2022 · 10:00 AM ET | Replay |
| GENinCode (LSE:GENI) — Interim Results Investor Presentation | Thu, Sep 16, 2021 · 11:00 AM ET | Replay |
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Private placement of new Ordinary Shares (Additional Subscription Shares) Announced: £580,000 · GBX 1 a share Use of proceeds: Additional funding and a longer cash runway while providing the FDA with updates for the De Novo application for its CARDIO inCode-Score test | Feb 6, 2026 | US$789,256 |
| New Ordinary Shares (WRAP Retail Offer) Closed: £200,000 raised · GBX 1 a share · Winterflood Securities Limited Dealers: Winterflood Securities Limited | Jan 26, 2026 | US$273,712 |
| Private placement of new ordinary shares (Placing Shares) Announced: £2.6M · GBX 1 a share · Cavendish Capital Markets Limited +2 Dealers: Cavendish Capital Markets Limited (co-lead), Oberon Capital (co-lead), Turner Pope Investments (TPI) Ltd (co-lead) Use of proceeds: US commercialisation and scale-up, EU and UK expansion, fundraising costs and general working capital | Jan 21, 2026 | US$3.49M |
| Private placement of new ordinary shares (Subscription Shares) Announced: £900,000 · GBX 1 a share Buyers: Nestor Oller (entities associated with existing shareholder Nestor Oller, with certain Directors, to subscribe for 87,300,000 Subscription Shares raising £0.9 million in aggregate) Insiders: Certain Directors intend to subscribe alongside entities associated with Nestor Oller | Jan 21, 2026 | US$1.21M |
| Private placement of new ordinary shares Update: Cavendish Capital Markets Limited +1 Dealers: Cavendish Capital Markets Limited (co-lead), Oberon Capital (co-lead) Buyers: Santi-1990 SL (Nestor Oller) (9,459,460 shares) | Mar 3, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in GBP
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 3.08M | 2.70M | 2.16M | 1.43M | 1.15M | 960.8K | 1.92M |
| Cost of revenue | 1.54M | 1.27M | 1.14M | 798.0K | 561.0K | 437.8K | 882.2K |
| Gross profit | 1.54M | 1.43M | 1.02M | 632.0K | 593.0K | 523.0K | 1.04M |
| Research and development | 145.0K | 334.0K | 72.0K | 1.00K | |||
| Selling, general and administrative | 1.75M | 1.86M | 7.75M | 6.27M | 2.01M | 1.55M | 204.8K |
| Operating income | -5.89M | -5.13M | -7.15M | -5.90M | -3.53M | -1.05M | -497.4K |
| Depreciation and amortization | 266.0K | 347.0K | 351.0K | 163.0K | 35.0K | 22.8K | 21.2K |
| EBITDA | -5.63M | -4.79M | -6.80M | -5.74M | -3.50M | -1.03M | -476.3K |
| Interest expense | 13.0K | 48.0K | 48.0K | 20.0K | 1.21M | 8.20K | 7.97K |
| Income before tax | -5.86M | -5.08M | -7.02M | -5.75M | -4.14M | -1.05M | -512.6K |
| Income tax | -158.0K | -649.0K | -7.00K | -187.0K | 6.00K | 116.0K | -108.8K |
| Net income | -5.71M | -4.43M | -7.02M | -5.56M | -4.14M | -1.17M | -403.7K |
| Earnings per share, basic | -0.02 | -0.03 | -0.07 | -0.06 | -0.08 | -0.01 | -6.03 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | 827.0K | 1.11M | 2.48M | 9.73M | 14.6M | 2.00M | 85.1K |
| Short-term investments | 68.0K | 55.0K | 42.0K | 16.0K | 4.00K | 2.00K | |
| Receivables | 948.0K | 610.0K | 509.0K | 614.0K | 265.0K | 241.2K | 301.4K |
| Inventory | 73.0K | 126.0K | 84.0K | 20.0K | 14.0K | 18.2K | -107.6K |
| Current assets | 2.04M | 2.10M | 3.19M | 10.5M | 15.0M | 2.27M | 386.6K |
| Property, plant and equipment | 1.00M | 46.0K | 11.0K | 7.42K | |||
| Goodwill | 0 | 149.0K | 149.0K | 0 | |||
| Total assets | 2.38M | 2.66M | 4.19M | 11.8M | 15.2M | 2.42M | 489.1K |
| Accounts payable | 1.28M | 612.0K | 1.19M | 1.42M | 345.0K | 193.0K | 386.5K |
| Current liabilities | 2.20M | 1.38M | 2.50M | 2.18M | 831.0K | 563.5K | 929.1K |
| Total debt | 146.0K | 234.0K | 299.0K | 354.0K | 330.6K | ||
| Total liabilities | 2.25M | 1.54M | 2.90M | 3.90M | 1.49M | 563.5K | 929.1K |
| Shareholders' equity | 124.0K | 1.13M | 1.29M | 7.90M | 13.7M | 1.86M | -440.0K |
| Shares outstanding | 274.3M | 175.0M | 95.8M | 95.8M | 50.5M | 114.4M | 67.0K |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -4.07M | -5.17M | -7.51M | -3.76M | -3.02M | -1.04M | -190.7K |
| Capital spending | -44.0K | -49.0K | -38.0K | -849.0K | -145.0K | -68.3K | -123.7K |
| Free cash flow | -4.11M | -5.22M | -7.54M | -4.61M | -3.17M | -1.11M | -314.4K |
| Cash from investing | -44.0K | 50.0K | 136.0K | -849.0K | -145.0K | -68.3K | -123.7K |
| Cash from financing | 3.64M | 3.65M | -94.0K | -47.0K | 15.9M | 3.03M | 400.3K |
| Change in cash | -283.0K | -1.37M | -7.25M | -4.82M | 12.6M | 1.92M | 85.3K |
Cap table
Built by 6ix from GENinCode PLC’s releases · as of Feb 6, 2026
- Common shares
- 753,041,137
- Fully diluted
- 753,041,137
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 753,041,137 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 753,041,137 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Bill Rhodes | Independent Non-Executive Chairman · Since at least Nov 4, 2026 |
| Felix Frueh | Non-Executive Director · Since at least Jan 21, 2026 |
| Huon Gray | Independent Non-Executive Director · Since at least Feb 9, 2026 |
| Jordi Puig | Chief Operations Officer · Since at least Feb 9, 2026 |
| Matthew Walls | Chief Executive Officer · Since at least Sep 29, 2026 |
| Paul Foulger | Chief Financial Officer · Since at least Sep 29, 2026 |
| Sergio Olivero | Independent Non-Executive Director · Since at least Feb 9, 2026 |
Log in to ask 6ix AI your own questions about GENinCode PLC.